NMDA receptor glycine-site partial agonist

Plain-language summaryIntrigue 70 / 100

D-cycloserine is an old tuberculosis antibiotic isolated from a Streptomyces bacterium and approved in 1956. Decades later researchers noticed it also acts as a partial agonist at the NMDA glycine site, meaning it activates the receptor but only about halfway. That partial behavior makes its effect dose-dependent: at low doses it boosts NMDA function (because endogenous co-agonists are not saturating the site), at high doses it actually competes with the full natural agonists and dampens NMDA signaling. The low-dose facilitating effect inspired its use as an extinction-learning enhancer paired with exposure therapy for phobia, PTSD, OCD, and social anxiety. Trials show modest effects with strict timing requirements (give it shortly before therapy or it does not work). Canonical NMDA glycine-site partial agonist. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

49/100

The canonical NMDA glycine-site probe, clinically useful but past peak novelty in extinction-learning research

Look, D-cycloserine is one of those compounds that lives two separate lives, and you have to score both honestly. As an antibiotic it’s been FDA-approved since 1956 and is thoroughly, almost painfully, understood. As an NMDA glycine-site partial agonist it became one of the more interesting pharmacological tools of the 1990s and 2000s, and that second life is why it belongs in this library at all.

The mechanism is genuinely worth understanding. D-cycloserine sits at the NMDA receptor glycine co-agonist site and behaves as a partial agonist with roughly 40-60 percent intrinsic activity. That creates a bidirectional dose-response profile that most researchers find counterintuitive at first: at concentrations below the endogenous glycine/D-serine tone, it potentiates NMDA function; at higher concentrations it competes with the full co-agonists and acts as a functional antagonist. The extinction-learning hypothesis follows directly from that lower-dose facilitating effect. NMDA receptor activation during extinction memory consolidation is necessary for durable fear reduction, and pre-session dosing with D-cycloserine was supposed to amplify exactly that window. It’s elegant pharmacology on paper.

What we dont love is what the clinical literature actually delivered. The extinction-learning trials in PTSD, OCD, phobia, and social anxiety disorder span two decades and multiple serious groups, including Michael Davis’s lab at Emory, Edna Foa’s group, and several independent European programs. The results are real but modest and frustratingly timing-dependent. Get the dosing window wrong and you may consolidate a worse extinction session rather than a better one. Meta-analyses have consistently struggled to show a clean, reproducible effect across disorders. The signal isn’t gone, but it’s smaller and less reliable than the early data suggested. Translational enthusiasm has cooled appropriately.

Here’s the thing, though: as a bench tool this compound is essentially irreplaceable. If you’re running any research program that touches NMDA receptor glycine-site pharmacology, fear extinction circuits, or the interface between NMDA modulation and behavioral plasticity, D-cycloserine is the reference standard. Nothing else occupies this exact pharmacological niche with its combination of FDA approval, known PK, and decades of protocol literature. For investigators in those areas it’s not optional; it’s the probe you reach for first when you need to ask whether glycine-site occupancy is doing the work you think it is.

We’d call it a niche probe with a legitimate but fully mature research story. The interesting questions it can still answer are mechanistic and tool-level questions, not frontier indication questions. Score reflects that honestly: high bench value, genuine differentiation within its niche, but novelty and translational excitement that belong to the 2000s rather than right now.

Novelty: 20
Mechanism promise: 50
In-category differentiation: 62
Evidence quality: 60
Translational signal: 42
Research bench value: 75

Rationale D-cycloserine scores well on bench value as the reference glycine-site partial agonist and holds a differentiated position as the defining compound in that niche, but its 1956 vintage, well-characterized mechanism, and a clinical literature that has delivered mixed results over three decades drag novelty and translational signal into the basement. No structural cap applies; the score reflects genuine probe utility without the novelty premium.

NMDA receptor glycine-site partial agonist

An antibiotic with NMDA receptor partial agonist activity; investigated as an extinction-learning enhancer in exposure therapy for anxiety disorders.

Abstract

D-cycloserine ((4R)-4-amino-1,2-oxazolidin-3-one; CAS 68-41-7; molecular formula C3H6N2O2; molecular weight 102.09) is a cyclic amino acid antibiotic isolated from Streptomyces orchidaceus and approved by the FDA in 1956 for second-line tuberculosis treatment. The compound is a partial agonist at the NMDA receptor glycine site (intrinsic activity approximately 40 to 60 percent), and the partial agonism produces dose-dependent NMDA receptor modulation: at low concentrations relative to endogenous glycine/D-serine, D-cycloserine functions as a positive modulator (enhancing NMDA function); at higher concentrations it competes with the full-agonist endogenous co-agonists and behaves as a functional antagonist. The lower-dose facilitating effect underlies use as an extinction-learning enhancer in exposure therapy for phobia, PTSD, OCD, and social anxiety; clinical trials have shown modest effects with timing-dependent results (administration shortly before therapy session is critical). Plasma half-life is approximately 10 hours. Used as the canonical NMDA glycine-site partial agonist in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-377Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: NMDA receptor glycine-site partial agonist

D-Cycloserine

Abstract

Read the full monograph